In comparing the predictive ability of TRIM28 to that of standard biomarkers, we found that TRIM28 has advantages in predicting NSCLC patients' immunotherapy outcomes (Ruppin2021_PD1_NSCLC, AUC = 0.66, Figure 6C). Here, TRIM28 is linked to non-small cell lung carcinoma.